drugset / Trial / NCT02661854

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy

NCT02661854 ↗

Phase 2 Unknown 186 enrolled Inmunotek S.L.
RandomizedParallel-groupDouble-blindScreening

Summary

The purpose of the study is to evaluate the more efficient dose for the treatment of rhinitis/rhinoconjunctivitis against mite allergy

Timeline

Start
2016-06-21
Primary completion
2020-07
Completion
2020-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MM09 Mannosylated Unknown 5000 unknown Subcutaneous
Subject MM09 Mannosylated Unknown 10000 unknown Subcutaneous
Subject MM09 Mannosylated Unknown 30000 unknown Subcutaneous
Subject MM09 Mannosylated Unknown 50000 unknown Subcutaneous

Indications